InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,994.46
(
0.36%
)
US TECH 100
20,550.80
(
0.04%
)
Dow Jones
43,986.08
(
0.59%
)
Brent Oil
73.89
(
-2.09%
)
Bitcoin
76,651.87
(
0.99%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120695
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dodah_2 post# 3818

Friday, 06/15/2007 11:13:07 PM

Friday, June 15, 2007 11:13:07 PM

Post# of 19309
Here’s Merrimack’s PR on the new U.S. patent for
MM-093. The 2025 patent expiration includes five
years of statutory extension under the Hatch-Waxman
act. Of interest is what this PR does not say: there is
no longer any mention of the MM-093 program in
psoriasis. If indeed the psoriasis program has been
terminated, the remaining MM-093 programs are the
ones in RA and uveitis.

http://biz.yahoo.com/prnews/070612/netu041.html?.v=9

>>
Merrimack Pharmaceuticals Receives U.S. Patent Covering Composition of Matter for Recombinant, Non-Glycosylated Human Alpha-fetoprotein; Extends Patent Protection of MM-093 to 2025

CAMBRIDGE, Mass., June 12 /PRNewswire/ -- Merrimack Pharmaceuticals announced today the issuance of a patent from the United States Patent and Trademark Office covering the composition of matter for recombinant, non-glycosylated human alpha-fetoprotein, referred to as MM-093. U.S. Patent No. 7,208,576 entitled, "Non-glycosylated Human Alpha-fetoprotein, Methods of Production, and Uses Thereof" was filed in 2003 and provides patent protection in the U.S. into 2025 including already accrued patent term extension time.

"This patent significantly strengthens our intellectual property portfolio surrounding MM-093 and the commercial life of this important product," said Robert Mulroy, President & CEO of Merrimack Pharmaceuticals. "We continue to view MM-093 as a novel and highly differentiated therapeutic that could have a significant impact in the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, uveitis, inflammatory bowel disease and psoriasis, among others."

MM-093, Merrimack's lead product, has completed several clinical trials including a Phase 1 study in healthy volunteers, a pilot study in RA patients and an exploratory, dose-ranging Phase 2 study. These studies have demonstrated that MM-093 is well tolerated and bioactive in addressing the signs and symptoms of RA. The Company is currently conducting an additional Phase 2 study in RA patients as well as a Phase 2 pilot study of MM-093 in patients with autoimmune uveitis. [Note that the psoriasis program is not mentioned in this paragraph.]

Merrimack controls a strong intellectual property estate around MM-093 comprised of 15 patents and a number of pending applications, both in the U.S. and internationally, covering composition of matter, production methods, and therapeutic uses.

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis, psoriasis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up